Bloom Health Partners CEO To Speak At Health Benefits Nation Conference In Orlando |

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces its CEO, Andrew Morton, will speak on a panel at Health Benefits Nation Conference in Orlando, Florida on September 15th, 2022.

Mr. Morton will join co-panelists Eric Hargan, former U.S. Federal Deputy Secretary of the Department of Health and Human Services (DHHS), and Jeff Hogan, President of Upside Health Advisors. The panel titled "Incorporating Occupational Health into Value Based Health Strategies" will focus on workplace health and using data models to improve outcomes in occupational health in such areas as preventive care and mental health.

Health Benefits Nation is the premier event attended by Chief Human Resource Officers, Chief Financial Officers, Human Resources, Benefits Executives and Benefits Advisors to break away from the status quo and accelerate the move to accountable, transparent, and high-quality employer healthcare. This well attended conference runs September 14th -16th, 2022.

For information on the Health Benefits Nation conference go to: https://healthbenefitsnation.com.

About Bloom Health Partners Inc. Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information: info@bloomhealthpartners.com

On behalf of the board of directors,

Andrew Morton, Chief Executive Officer

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/136181

News Provided by Newsfile via QuoteMedia

Advanced health for employees is quickly becoming an essential part of running an organization. The pandemic created a focus on health and safety in the workplace. As we move to a post-pandemic world, many organizations are faced with a need to look at long term employee health as a part of their operations. A tight labor market with a shortage of workers has put employers in a position where they need to focus on retaining employees while finding innovative ways to attract new talent. This is happening at the same time that individual health needs are catching up after 2 years of pandemic management.

Today, companies are increasingly seeking find ways to mitigate what is expected to be a decade of demanding employee needs, rising healthcare costs and a need for accurate risk management. This all comes at high cost to organizations in lost productivity and ever- increasing health and liability insurance fees. Industry experts and top investors are taking notice of global opportunity for employer provided health services. Larry Fink, CEO of Blackrock recently discussed on CNBC that worker health is “the new world of work…companies not adapting do so at their own peril”.*

Given the new era of ‘safety culture,’ in workplaces, it’s no surprise that the global workplace safety market size is expected to reach US$19.9 billion by 2025. The market is estimated to grow from an estimated value of US$12.1 billion in 2020 at a compound annual growth rate of 10.4 percent from 2020 to 2025. With an occupational health market in the workplace in 2021 of over US$6.5B in the US, it’s expected this market with rise significantly. Innovation in workplace health is needed to meet growing demand.

Bloom Health Partners (CSE:BLMH,OTCQB:BLMHF,FRA:D84) offers a global platform that provides healthcare security, diagnostic testing and occupational health-tech solutions. The company’s mission is to ensure that “Unstoppable is Possible'' for businesses and their employees through innovative and customized healthcare models. Bloom Health Partners serves several key markets, with services that include onsite healthcare, advisory services, K-12 school testing, television and film production sets, workplaces and live events.

Bloom Health Partners’ end-to-end healthcare delivery models are connected to its software platform with various solutions, including occupational health services, a data platform that manages end-to-end health intelligence, primary care services, employee screening and preventative care, laboratory services, Covid-19 and flu testing and vaccinations, employee healthcare maintenance and management, mental health services and wellness programs.

Bloom Health Partners’ platform empowers businesses and organizations to create strategies to manage health and safety while engaging employees. The company’s system is a stable, flexible, scalable and integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes. Bloom Health Partners’ platform is Android, Apple and smartwatch compatible.

The company’s platform provides businesses and organizations with a competitive advantage through the reduction in lost time and productivity, worker’s compensation claims, disability costs, insurance premiums, retention and recruitment challenges compared to the traditional workplace care model. The traditional workplace care model relies primarily on emergency first aid, off-site ER and outside clinics. Bloom Health Partners’ platform provides better and more convenient healthcare from pre-employment drug testing, health screening and job duty and function assessments to advanced on-site clinical care and telehealth and monitoring services.

Bloom Health Partners is trusted by multiple Fortune 500 companies, major film production companies, large entertainment venues, schools, manufacturing facilities and more to handle Covid-19 testing and safety compliance. The company’s major clients include PepsiCo, Netflix, Six Flags, Amazon Studios, Apple TV+, Live Nation, Sony and Viacom CBS. To date, Bloom Health Partners clients have remained operational and avoided Covid-19-related shutdowns and delays. This has placed Bloom in a strong position to work with large organizations as they evolve into longer-term health needs for employees.

The company is led by a world-class team with a science-first approach. Bloom Health Partners’ board consists of foreign pharmaceutical executives and the chief medical officer of GE Corporate. Bloom Health Partners also owns and operates its best-in-class labs in major cities in the United States, including Los Angeles, Dallas, Atlanta and Montgomery, Alabama. The company’s labs serve as a support network for it’s growing employer health business.

The company has an established and diverse revenue stream with the potential for further growth. Bloom Health Partners’ revenue model stems from health (?) and annual recurring services as well as from its research and advisory services. The company’s health and annual recurring revenue consist of software platform revenue, occupational health and testing revenue. Bloom Health Partners’ research and advisory revenue consist of consulting and research revenue.

The company plans to take advantage of the growing opportunity in the new health-tech space as Bloom Health Partners plans to open new facilities and expand its offices in the United States and Canada in 2022. Health is becoming an essential part of running a business and Bloom is pioneering the model.

Core to Bloom’s business is it’s software platform call Bloom Shield. Bloom’s platform manages data and results for organizations to effectively use Blooms services. As a secure cloud platform, Bloom Shield is designed to handle personal health information and provide Bloom clients a planning tool to help make decisions to keep their organizations running. As clients use Bloom services, such as a large employer or film production, business leaders can see an overview of health without any compromise to individual privacy. This big data platform provides organizations much needed tools to stay operational based on all health conditions of workers.

Bloom Health Partners’ safety and testing services consist of lab-based services for parts of industry and schools that will require ongoing pandemic screening. This proven model is evolving into testing of all kinds such as cancers, diabetes and drug testing. Bloom’s network of labs are able to support both pandemic and post pandemic testing needs efficiently.

All testing from labs are easily accessible through the company’s secure online reporting portal. Patients can register their samples and view results while administrators can log in to monitor compliance, track samples and manage contact tracing. The company provides customized client portals as well as third-party software integration capabilities. All of which serve as a baseline for multiple health services.

Bloom Health Partners’ on-site healthcare services consist of a variety of customized clinical care solutions delivered through its Bloom Care platform. These services include:

The Company’s onsite healthcare helps businesses manage several of the largest health-related expenditures for businesses through prevention, management and treatment. These health-related expenditures include cardiovascular health, obesity-related complications, pulmonary illnesses, behavioral health conditions, musculoskeletal injuries and/or pain and mental health. Bloom Health Partners seeks to help businesses reduce sick days and provide quality assurance while improving patient care.

The Company performed in-depth consultations for businesses with scientists and doctors to establish a customized program design based on needs, timeline, budget and location. Bloom Health Partners also provides businesses with operations and logistics support, customer service and communication 7 days a week from a dedicated advisor.

Bloom Health Partners’ advisory services consist of extensive planning and consulting provided by its team of doctors, scientists and industry experts. The company’s advisory team strictly adheres to guidelines from the CDC, FDA, HHS, OSHA, WHO, IPAC, and equivalent local organizations. The company’s advisory team delivers strategy and implementation recommendations to establish proactive healthcare safety plans based on needs, timeline, budget and location.

Bloom Health Partners’ advisory team validates scientific research and tracks data from around the world to ensure accurate and up-to-date advice. The team is committed to always ensuring clients are informed with updates when they desire it –– allowing clients to set preferred frequency updates. The company’s advisory team goes above and beyond to secure necessary supplies and resources, seamlessly execute safety plans and adapt to changes in real-time.

Bloom Health Partners’ K-12 school services consist of a Covid-19 screening program structured to specifically serve the needs of students and schools. The K-12 school service provides on-site, customized, non-invasive and accurate PCR testing weekly. The samples are transported by Bloom Health Partners’ team to a nearby Bloom Health Partners lab and produce results in 24 hours. The company’s approach provides enhanced reliability, transparency, communication, HIPAA-compliant reporting and accountability for schools.

The K-12 school testing is conducted by Bloom Health Partners professional staff with training in the most effective, accurate, comfortable test sample collection techniques. The service is managed end-to-end by Bloom Health Partners’ team to minimize disruptions and reduce the workload of the school staff. The company maintains patient privacy and only shares results for public health purposes.

Bloom Health Partners production services consist of testing for television and film production sets. The company provides on-site collection, flexible scheduling, reporting and customized solutions for productions.

The company’s end-to-end testing for productions has resulted in keeping movie and TV sets running. Bloom Health Partners exceeds the CDC’s requirement of testing one protein by testing the gold standard of three proteins to reduce false positives. This same approach can be brought to productions to cover an array of health needs.

Bloom Health Partners is trusted by several small-scale and large-scale production companies –– including Netflix, Apple TV+ and Sony –– to handle testing and safety compliance.

Sav DiPasquale is a senior executive with over 30 years of experience in the pharmaceutical, biotechnology and transportation industries. He is currently the president of the Canadian Pharmaceutical Distribution Network ("CPDN"). Previously, DiPasquale spent nearly 17 years at GlaxoSmithKline in various senior positions, including vice president of business development and CIO. He is also the former president and CEO of Orgenesis.

Jessica Federer is a venture partner with Boston Millennia Partners. Federer is also an advisor and investor for health and technology companies. She is on the United Nations m-Powering Development Advisory Board for the Agency for Information and Communications Technology (ITU). She is also the founder of Innovayte. Previously, Federer was the chief digital officer at Bayer A.G. which is a global life science leader. At Bayer A.G., Federer led a digital transformation across consumer health, pharmaceuticals, animal health and agriculture.

Dr. Nimisha Kalia is currently the chief medical officer at GE Corporate. She is board-certified in internal medicine, occupational medicine and public health and general preventive medicine. Among her many achievements, Dr. Kalia held academic appointments at Johns Hopkins University School of Medicine, the Johns Hopkins Bloomberg School of Public Health and the Dell Medical School at the University of Texas in Austin.

John Garcia is a seasoned senior executive who spent 32 years in the telecommunications industry. He spent the last 12 years of his career at Sprint where he held pivotal roles, including chief marketing officer and president of wireless. Garcia has also engaged in several major consulting projects for multiple companies, including VRide, and Otsuka Pharmaceuticals. His experience also includes a major consulting project for YRC which is the nation's largest less than truckload (LTL) carrier.

Andrew Morton is a seasoned global technology executive with a track record of successfully building and running innovative companies. Morton was the senior vice president of global sales for Zodiac Interactive. Zodiac Interactive is a privately-held software company focused on advanced software for tier 1 cable and telecommunications providers. He headed up broadband television for Entone where he launched successful operations on multiple continents. Entone was acquired by Amino Communications (LON:AMO). Morton served for several years post-transaction on the senior executive team. Morton also co-launched global operations for Comtrend Corporation which is a leader in telecom hardware and software. Earlier in his career, he held growth roles at 3Com and IBM’s spinoff company Lexmark.

Abbas Khan is the managing partner and co-founder of Bloom Health Partners. Khan is a true collaborator with a knack for building teams and implementing creative solutions, Khan embodies Bloom Health Partner’s mission to ensure “unstoppable is possible.” His entrepreneurial spirit and strategic thinking have been instrumental in forming key partnerships to grow Bloom’s client base in the U.S. and expand its best-in-class clinical operations to other countries.

Before working with Bloom, Khan served as the business development and marketing manager for Life Biosciences. Khan was also the commercialization director for CloudMex which is a cutting-edge health tech company. At CloudMex, he led the rebrand of their communication strategy as well as managed their partnership and product development with Anthem Health. His background also includes strategic marketing roles at Sterling-Rice Group and PepsiCo. Khan is currently pursuing his MBA in Healthcare at the Yale School of Management.

Outside of work, Khan enjoys time with his family. Khan and his wife support charitable causes through their family’s foundation called The Khan Family Foundation. The Khan Family Foundation was founded by his philanthropist mother and father. The Khan Family Foundation actively focuses its charitable giving on underserved youth, education initiatives and women’s empowerment.

Cole Lysaught is a managing partner and co-founder of Bloom Health Partners. Lysaught is

an entrepreneur at heart. He brings a strong background in financial and operational leadership. He has an extensive track record in investing and scaling new and existing portfolio companies, investment management, building teams and guiding operations.

Before working at Bloom, Lysaught was a partner at Ahkeo Ventures which is an early-stage venture capital firm. Since 2011, he has facilitated over US$1 billion in transactions across a wide range of industries, including energy, banking, hospitality and tourism. Lysaught continues to build value as a leader and investor at CPL Investments which is an investment management firm. Lysaught also currently serves as the managing partner of CPL Investments.

Lysaught serves as a US Delegate to the G 20 Entrepreneurial Summits in Toronto and Mexico City. He also serves on the Dallas Alumni Board of Directors at Texas Christian University. Previously, he spent six years as a host committee member for the Great Investors’ Best Ideas Foundation (GIBI). GIBI is a nonprofit organization that benefits The Michael J. Fox Foundation for Parkinson’s Research and the Vickery Meadow Youth Development Foundation. He graduated cum laude from Texas Christian University with a BBA in Finance and Entrepreneurial Management.

Marlis Yassin is a CPA and CA with more than 15 years of experience working with publicly-listed companies. She has held finance management positions at various public companies, including an international industrial products company and mid-tier mining companies. Yassin gained extensive experience through her client engagements at Deloitte. Yassin provided reporting, advisory and assurance services to publicly traded companies, primarily in the natural resources sector.

Andrew McCan was the co-founder and CTO of DeviantArt, a Hollywood-based online artist platform, acquired by Wix in 2017. At the time of the acquisition, DeviantArt had over 40 million users and 325 million pieces of original art housed on the platform. Previously, he co-founded Mediascience which was acquired by Lycos. He also built Sonique which is an audio player application for the Windows platform. McCan studied computer science at Montana State University.

Rosemary Elliston served as Chief Client and Operations Officer at International Capital and Management Company - ICMC, where she led an exceptional stakeholder team providing inventive solutions and expanding business capabilities to Cancer Treatment Centers of America. During her tenure for the ICMC family of companies she held senior roles including CEO. Rosemary has led multiple highly visible projects and teams with industry leaders such as Kaiser Permanente, Andersen Consulting, Perot Systems and Blue Cross Blue Shield. Rosemary majored in Medical Technology at the University of South Alabama in Mobile, AL and is an alumna of the Executive Development Program from The Wharton School of the University of Pennsylvania.

Mehmood Khan M.D. has diverse experience in the pharmaceutical, clinical and consumer industries. Dr. Khan brings a wealth of knowledge to his role as the senior health advisor at Bloom Health Partners. Dr. Khan is currently the chairman and chief executive officer of Life Biosciences Inc. At Life Biosciences, he provides strategic direction and operational oversight across the company and its six daughter companies. His vision of a more efficient and effective drug development pathway will drive innovation in the science and technology that Life Biosciences advances.

Dr. Khan previously served as the chief scientific officer and vice chairman at PepsiCo which is a Fortune 500 company. Before joining PepsiCo, Dr. Khan served as the president of Takeda Pharmaceuticals which is one of the largest pharmaceutical companies in the world. At Takeda Pharmaceuticals, Dr. Khan led the global efforts by revenue. Earlier in his career, Dr. Khan had a distinguished medical career as a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School. He served as the director of diabetes, endocrine and nutritional trials unit at the Mayo Clinic and Mayo Medical School.

Dr. Khan is the recipient of numerous distinctions and awards, including The Harris Award for Excellence in Food and Science Technology and a Harvard University Illuminate Global Award for Innovation. Dr. Khan was named one of the 100 Most Creative People in Business by Fast Company. Dr. Khan has also held leadership roles on numerous boards. He currently serves as chairman of the U.S. Council on Competitiveness, V-Cat Board Member and NIST Board Member.

Dr. Khan earned his medical degree from the University of Liverpool Medical School in England. He completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota in Minneapolis. He is a Fellow of the Royal College of Physicians in London and a Fellow of the American College of Endocrinology.

Dr. James Shepherd is one of the world’s foremost experts in infectious diseases. Dr. Shepherd is an associate professor of medicine at Yale School of Medicine. Dr. Shepherd’s global experience includes his work as a special advisor to the World Health Organization. His recent experience includes advising the government of India on tuberculosis control. Dr. Shepherd also directed a research program in TB and HIV for the Centers for Disease Control and Prevention in Botswana. He also assisted the University of Maryland in starting a large AIDS treatment program in Nigeria.

Honorable Eric D. Hargan, JD, is the senior health advisor for Bloom Health Partners. He was a former Deputy Secretary of the United States Department of Health and Human Services (HHS) which is the largest department in the federal government. As Deputy Secretary of HHS, he oversaw the development and approval of all HHS, CMS and FDA regulations and provided significant guidance. Hargan also oversaw the department’s day-to-day operations and management as well as led policy and strategy development.

Hargan served on the board of Operation Warp Speed where he signed the first document that enabled the start of Operation Warp Speed. This was a public-private partnership initiated by the U.S. government to facilitate and accelerate the development, manufacturing and distribution of Covid-19 vaccines, therapeutics and diagnostics. He also was a board member at University Hospitals and Alio Medical. Hargan is also a Fellow at the Health Evolution Forum.

Alexander Stemer, M.D. is board certified in internal medicine and infectious disease. Dr. Stemer brings more than 42 years of experience to the Bloom Health Partners team. He was recently named the American Heart Association Heart of Gold Executive Chairman for 2022.

Dr. Stemer welcomes the challenge of solving new problems. He has been instrumental in the fight against Covid-19, developing infection control programs and protocols for hospitals and skilled nursing facilities. In addition to serving as associate clinical professor of medicine at the Indiana University School of Medicine, Dr. Stemer currently serves as the co-chair of the Symphony Health Network Covid-19 Task Force. He also recently worked with the National Institute of Health and Eli Lilly to develop study protocols for the prevention and treatment of Covid-19 in skilled nursing facilities using a monoclonal antibody. The study was approved by the FDA, completed and recently published in the Journal of the American Medical Association.

Joe Kurland is a vaccine specialist and infection preventionist at Children’s Minnesota. Kurland is an experienced infection control practitioner with a demonstrated history of working in acute and ambulatory care fields. Kurland is skilled in epidemiology, infection prevention, high-level disinfection and sterilization processes and construction risk assessments (ICRA). Kurland is also an experienced professional providing legionella risk evaluation, pandemic response and vaccine-related advice.

New Bloom lab will support operations in the Honolulu area and surrounding region

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces the opening of a new location in in the Honolulu area.

The new location provides expanded laboratories for operational health services and diagnostic testing to meet continued demand. Bloom has also added a local team. The Honolulu location will serve film/TV productions in addition to new opportunities with local businesses and organizations in the surrounding area.

"Adding services in Honolulu shows flexibility in our business model," said Andrew Morton, CEO of Bloom. "We've shown the local market in the Hawaiian islands our willingness to bring services directly to them. The clients that brought us to Hawaii are a great baseline for Bloom to prove out a longer term model of support for health services across the United States. We continue to be focused on delivering technology enabled, operational health services to large employers."

The Company also announces that in connection with closing the second tranche of its previously announced non-brokered private placement offering (the "Offering") on July 18, 2022, total compensation paid was C$33,240 and 166,200 compensation options, and not as previously indicated. All securities issued in connection with the Offering are subject to a statutory hold period until November 19, 2022 in accordance with applicable securities laws.

For more information: info@bloomhealthpartners.com

On behalf of the board of directors,

Andrew Morton, Chief Executive Officer

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137059

News Provided by Newsfile via QuoteMedia

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces unaudited Fiscal Q2 2022 revenues of CAD $8.4M for the three months ended June 30th, 2022, bringing year-to-date revenues to CAD $24.9M for the first three quarters of Fiscal 2022.

Full results available at www.sedar.com.

"We're thrilled to announce our third quarter results," said Andrew Morton, CEO of Bloom. "Our Fiscal Q3 2022 revenue of CAD $8.4M and aggregate CAD $24.9M year to date has resulted in us all but reaching our revenue guidance for FY 2022 in three quarters. We're proud of our team's performance so far this year as we continue to transition Bloom into an innovative provider of employer health-tech solutions and services. Our end-to-end platform strategy of clinical, labs and data in workplace health is well received by clients, partners and investors."

(1) This is a non-IFRS measure. Refer to the section "Non-IFRS Financial Measures" for information on the calculation of this non-IFRS measures. (2) Refer to the section "Disclosure on Financial Guidance" for additional information.

We believe that providing certain non-IFRS financial measures provide users with important information regarding the operational performance of our business. The non-IFRS financial measures used by management do not have any standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other issuers. Accordingly, these measures should not be considered as a substitute or alternative for IFRS measures as determined in accordance with IFRS. By considering these measures in combination with the comparable IFRS financial measures, we believe that users are provided a better overall understanding of our business and financial performance during the relevant period than if they considered the IFRS financial measures alone.

EBITDA is defined as earnings before interest, income taxes, depreciation, and amortization and is utilized by management to assess and evaluate the financial performance of its operations. Management believes that EBITDA improves comparability between periods by eliminating the impact of interest, income taxes, depreciation, and amortization.

Adjusted EBITDA excludes items that are not considered to be indicative of operational and financial trends either by nature or amount to provide a better overall understanding of the Company's underlying business performance. The most directly comparable GAAP measure to EBITDA and Adjusted EBITDA is net income before tax, calculated as follows:

The most directly comparable GAAP measure to EBITDA is net income before tax, calculated as follows:

Anticipated revenue figures and EBITDA are based on modelling and estimates developed by management and updated as of June 30, 2022. These estimates are based on our Fiscal Year 2021 results and year-to-date 2022 results, including market size, and assume only ongoing business, as well as marginal growth in fixed costs through Fiscal Year 2022. Readers are cautioned that actual results could differ materially from these estimates based on increases in operating costs, failure to maintain regulatory licensing, inability to execute on existing contracts with schools in Texas, failure to attract and retain qualified employees, or a reduction in customer demand.

About Bloom Health Partners Inc.

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information: investors@bloomhealthpartners.com

On behalf of the board of directors,

Andrew Morton, Chief Executive Officer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/135425

News Provided by Newsfile via QuoteMedia

New Bloom lab in the Chicago area will serve as a foothold in the midwestern United States

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D84) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces the opening of a new location in the Chicago area.

The new location provides expanded laboratories for operational health services and diagnostic testing to meet continued demand. As part of this expansion, Bloom has also added a local team. The Chicago location will serve film/TV productions in addition to new opportunities with Fortune 500 and organizations in the surrounding area.

"Our Chicago presence will support our growth plans in one of America's busiest business regions," said Andrew Morton, CEO of Bloom. "We're focused on growing occupational health-tech for our clients. With supporting facilities in key hub cities like Dallas, Atlanta and now Chicago, Bloom is well-positioned to support current and future clients in strategic markets."

Bloom also announces it has closed the third and final tranche of its previously announced non-brokered private placement offering (the "Offering") and has issued 375,000 units (the "Units") at $0.20 per Unit for gross proceeds of C$75,000. Combined with the first and second tranche of the Offering, the Company has issued 8,295,000 Units for aggregate gross proceeds of C$1,659,000. The Units are comprised of (i) one (1) common share in the capital of the Company ("Common Shares"); and (ii) one-half (1/2) of a transferable common share purchase warrant (each whole warrant, a "Warrant" and collectively, the "Warrants"). Each Warrant entitles the holder thereof to acquire one (1) additional Common Share (each, a "Warrant Share") in the capital of the Company at a price of $0.30 per Warrant Share until December 26, 2023. The net proceeds of the Offering will be used by the Company for ongoing working capital and corporate development.

In connection with closing the third tranche of the Offering, the Company paid C$4,500 and issued 22,500 Warrants, exercisable at a price of $0.30 per Warrant Share until December 26, 2023 to an arms-length party who assisted in introducing subscribers to the Offering. All securities issued in connection with the Offering are subject to a statutory hold period until December 26, 2022 in accordance with applicable securities laws.

About Bloom Health Partners Inc. Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D84) is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information: info@bloomhealthpartners.com

On behalf of the board of directors,

Andrew Morton, Chief Executive Officer

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/134923

News Provided by Newsfile via QuoteMedia

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces that it has closed the second tranche of its previously announced non-brokered private placement offering (the "Offering") and has issued 2,770,000 units (the "Units") at $0.20 per Unit for gross proceeds of C$554,000. Combined with the first tranche of the Offering, the Company has sold 7,920,000 Units of the Company for aggregate gross proceeds of C$1,584,000. The Units are comprised of (i) one (1) common share in the capital of the Company ("Common Shares"); and (ii) one-half (12) of a transferable common share purchase warrant (each whole warrant, a "Warrant" and collectively, the "Warrants"). Each Warrant entitles the holder thereof to acquire one (1) additional Common Share (each, a "Warrant Share") in the capital of the Company at a price of $0.30 per Warrant Share until July 18, 2023. The net proceeds of the Offering will be used by the Company for ongoing working capital and corporate development.

In connection with closing the second tranche of the Offering, the Company paid C$32,640 and issued 163,200 Warrants, exercisable at a price of $0.30 per Warrant Share until July 18, 2023 to an arms-length party who assisted in introducing subscribers to the Offering. All securities issued in connection with the Offering are subject to a statutory hold period until November 19, 2022 in accordance with applicable securities laws.

The Company also announces that its board of directors has approved a change in the duties of an existing consultant to the Company, Spiro Kletas, to include advising the Company on shareholder communications and financing strategy. Mr. Kletas is presently compensated at a rate of $6,000 per month, and will continue at this rate. In consideration for his additional duties, Mr. Kletas has also been granted 150,000 incentive stock options, vesting over a twelve-month period and exercisable at a price of $0.40 until July 5, 2025.

About Bloom Health Partners Inc.

Bloom Health Partners Inc. is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information on the Company, please email investors@bloomhealthpartners.com

On behalf of the board of directors,

Bloom Health Partners Inc. Andrew Morton, Chief Executive Officer

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/131225

News Provided by Newsfile via QuoteMedia

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces that it has closed an initial tranche of its non-brokered private placement offering (the "Offering") and has issued 5,150,000 units (the "Units") at $0.20 per Unit for gross proceeds of $1,030,000. The Units are comprised of (i) one (1) common share in the capital of the Company ("Common Shares"); and (ii) one-half (12) of a transferable common share purchase warrant (each whole warrant, a "Warrant" and collectively, the "Warrants"). Each Warrant entitles the holder thereof to acquire one (1) additional Common Share (each, a "Warrant Share") in the capital of the Company at a price of $0.30 per Warrant Share until July 6, 2023. The net proceeds of the Offering will be used by the Company for ongoing working capital and corporate development.

The initial tranche of the Offering was led by Ascenta Finance Corp., an exempt market dealer based in Vancouver, British Columbia. In connection with closing the initial tranche of the Offering, the Company paid $39,900, issued 3,000 Warrants, exercisable at a price of $0.20 per Warrant Share until July 6, 2023, and 196,500 compensation options (each, an "Option") to certain arms-length parties who assisted in introducing subscribers to the Offering. Each Option is exercisable to acquire a Unit under the same terms as the Offering until July 6, 2023. All securities issued in connection with the Offering are subject to a statutory hold period until November 7, 2022 in accordance with applicable securities laws.

The Offering included participation by the Chief Executive Officer of the Company in the amount of 50,000 Units. The purchase constitutes a related-party transaction within the meaning of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions) ("MI 61-101"). The purchase is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of the Units issued to, and the consideration paid by, the Chief Executive Officer did not exceed twenty-five percent of the Company's market capitalization.

About Bloom Health Partners Inc.

Ascenta Finance, headquartered in Vancouver, BC, is an Exempt Market Dealer registered in the provinces of BC, Alberta, Saskatchewan, Manitoba and Ontario. Ascenta connects qualified investors with quality companies that provide compelling investment opportunities with significant upside potential.

For more information on the Company, please email investors@bloomhealthpartners.com

To express an interest in participating in the Offering, please contact Marshall Farris at Ascenta Finance Corp. (marshall@ascentafinance.com).

On behalf of the board of directors,

Bloom Health Partners Inc. Andrew Morton, Chief Executive Officer

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130200

News Provided by Newsfile via QuoteMedia

Oculus VisionTech Inc. (TSXV: OVT) (OTCQB: OVTZ) (FSE: USF1) is pleased to announce the results of its 2022 Annual General Meeting ("AGM"). The AGM was held on September 15, 2022 in Vancouver, British Columbia. All resolutions put forward at the meeting were approved by shareholders. A total of 60,059,026 common shares (65.69% of the 91,422,569 issued and outstanding shares of the Company entitled to vote as of the July 19, 2022 record date for the AGM) were present in person or by proxy, constituted a quorum for the transaction of business and were voted at the AGM. The agenda items submitted at the AGM were passed as described below. Percentages indicated below reflect the percentage of the total number of shares voted at the AGM with respect to that agenda item.

The detailed results of voting by ballot in respect of the election of directors were as follows:

There were 6,890,471 broker non-votes with respect to the election of directors. Votes that were withheld and broker non-votes were counted for the purposes of determining the presence or absence of a quorum but had not other effect on the election of directors.

To ratify the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the Company's independent public accounting firm for the fiscal year ending December 31, 2022. The votes cast for or against this agenda item, and the numbers of abstentions, were as follows:

There were no broker non-votes with respect to this agenda item. Abstentions were counted for purposes of determining the presence or absence of a quorum, and abstentions were deemed to be "votes cast" and had the same effect as a vote against this agenda item.

To approve the adoption of the Company's Omnibus Equity Incentive Compensation Plan. The votes cast for or against this agenda item, and the number of abstentions, were as follows:

There were 6,890,471 broker non-votes with respect to this agenda item. Broker non-votes and abstentions were counted for purposes of determining the presence or absence of a quorum. Abstentions were deemed to be "votes cast" and had the same effect as a vote against this agenda item. Broker non-votes were not deemed to be "votes cast", and therefore had no effect on the vote with respect to this proposal.

To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. The votes cast for or against this agenda item, and the number of abstentions, were as follows:

The detailed "Report of Voting Results" on all resolutions for the Company's AGM is available under the Company's profile on SEDAR, on the Company's website, in the Company's Current Report on Form 8-K as filed with the United States Securities and Exchange Commission available under the Company's profile on EDGAR or upon request by contacting the Company's Corporate Secretary at (604) 685-1017.

Oculus VisionTech Inc. (OVT), www.ovtz.com, is a cloud-native development-stage technology company focused on data compliance and digital privacy solutions for business customers worldwide. With offices in San Diego, California and Vancouver, British Columbia, the Company is currently expanding its' new ComplyTrust®www.complytrust.com, product suite which includes the ComplyScan® cloud data protection and compliance tool and Forget-Me-Yes® B2B data privacy Software-as-a-Service (SaaS) platform, optimizing CCPA, GDPR, LGPD and other regulatory compliance legislation for Salesforce organizations worldwide that provide businesses with secure data privacy tools enabling sustained and continuous global regulatory compliance of data subject rights. OVTZ's legacy Cloud-DPS digital content protection solution implements invisible forensic watermarking technology that seamlessly embeds imperceptible tracking components into documents and video-frame content that enables tamper-proof legal auditability for intellectual property protection.

Learn more about Oculus at www.ovtz.com or follow us on Twitter (https://twitter.com/OculusVT) or Facebook (https://www.facebook.com/OculusVisionTech/)

ComplyTrust Inc. https://complytrust.com/, a 100% wholly-owned subsidiary of Oculus VisionTech, is specifically focused on providing enterprise organizations and individuals with secure data privacy tools that provide sustained and continuous global regulatory compliance of data subject rights. Headquartered in San Diego, California, ComplyTrust was founded by industry veteran storage technology experts and is operated by an experienced management team.

Learn more about ComplyTrust at https://complytrust.com/.

Anton Drescher Telephone: (604) 685-1017 Fax: (604) 685-5777

Website: http://ovtz.com/ TSXV: https://money.tmx.com/en/quote/OVT/company#profile-section-company-spoke US OTC Markets (OTCQB): https://www.otcmarkets.com/stock/OVTZ/security Berlin Borse: https://www.boerse-berlin.com/index.php/Shares?isin=US67575Y1091 Frankfurt Borse: https://www.boerse-frankfurt.de/equity/oculus-visiontech

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements and information within the meaning of applicable securities laws (collectively, "forward-looking statements"), including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, statements as to the intended uses of the proceeds received from the Offering. Often, but not always, forward-looking statements can be identified by words such as "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to, among others, the change of business focus of the management of Oculus, the inability of Oculus to pursue its current business objectives, the ability of the Company to obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including TSXV final acceptance of the Offering and any planned future activities, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company's industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and Oculus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although Oculus believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate.

Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in Oculus' periodic reports filed from time-to-time with the United States Securities Exchange Commission and Canadian securities regulators. These reports and Oculus' public filings are available at www.sec.gov in the United States and www.sedar.com in Canada.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137336

News Provided by Newsfile via QuoteMedia

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically affirms that its pathogen killing technology SteriLumen's Airocide® and Lumicide are highly effective, differentiating solutions for addressing recent recommendations from the Centers for Disease Control (CDC) for cleaning and disinfecting settings that may be contaminated with Monkeypox and other orthopoxviruses.

In a recent publication, available here , the CDC provided considerations for disinfecting settings that may be contaminated with Monkeypox virus and highlighted the virus' sensitive to UV light, disinfectants and household cleaners in a tweet available here .

John F. Andrews Applied UV's CEO and Director stated, "As the only public, pure-play air and surface disinfection company, we are uniquely capable of capturing a significant portion of the emerging market opportunity affirmed by the CDC's recommendations. We have a growing list of business case uses for global, highly recognized customers such as Whole Foods, Del Monte, the Boston Red Sox, Opus One and Tru Infusion, across a diversity of vertical markets including healthcare, cannabis, correctional facilities, schools, wineries, dairy and food preservation that use our Airocide product suite and attest to its efficacy. The emergence of Monkeypox, which is an airborne and surface transmitted pathogen, presents an additional opportunity for us to apply our clinically-proven Airocide and Lumicide technologies to eradicate the virus from virtually any contaminated setting and reduce the risk of spread. Independent research has affirmed that orthopoxviruses, including Monkeypox, can survive in an environment for weeks or months and porous materials may harbor live viruses for longer periods of time. Airocide, which was developed for NASA and the University of Wisconsin at Madison, is more effective than ultra-violet (UV) solutions as it utilizes Photocatalytic Oxidation (PCO) technology to completely trap and destroy any and all carbon-based airborne viruses by oxidation without any harmful by-products, and our patented Lumicide surface and drain UVC technology will destroy any surface related Monkeypox virus. We are encouraged by the CDC's proactive efforts to provide guidance on ways to clean, disinfect and reduce the risk of spread, and we look forward to applying our industry-leading solution to help keep people healthy and safe."

The Airocide® System, originally developed for NASA with assistance from the University of Wisconsin at Madison, is an airborne pathogen killing technology that uses a patented combination of UVC and a proprietary, titanium dioxide based photocatalyst. Listed as an FDA Class II Medical device, the Airocide® technology is clinically proven and field tested to kill/remove/eliminate airborne pathogenic and non-pathogenic microorganisms, allergens, odors and harmful VOCs in a variety of applications and industries including healthcare, hospitality, grocery chains, wineries, commercial real estate, schools, dental offices and homes. Airocide® air purifiers are available at www.airocide.com .

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® air purification devices are research backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photocatalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005294/en/

For additional Company Information: Applied UV Inc. John F. Andrews Applied UV CEO, Director john.andrews@applieduvinc.com

Contact: Brett Maas, Managing Principal Hayden IR brett@haydenir.com (646) 536-7331

News Provided by Business Wire via QuoteMedia

dynaCERT Inc. (TSX: DYA) (OTCQX: DYFSF) (FRA: DMJ) (" dynaCERT " or the "Company") is pleased to announce its participation exhibiting at the IAA Transportation Trade Show 2022 being held from September 20 th to 25 th in Hanover, Germany. IAA Transportation, under the motto "People and Goods on the Move", is the world's largest platform for transport and logistics and will host over 2,000 exhibitors from across the world. More than 250,000 attendees are expected during the six days of the show.

At the IAA Transportation Trade Show 2022 dynaCERT will be exhibiting its proprietary HydraGEN™ Technology designed to reduce fuel consumption and pollutants such as GHG's currently available globally for small, medium and large diesel vehicles and generators.

IAA Transportation presents the world of buses, van, trucks, trailers and bodies in all its facets. The exhibition provides content for all aspects of sustainable, social, technical, economic and political aspects of global transport. International opinion leaders from all relevant industries will be discussing the challenges of our time and present their solutions and visions for the global and regional transport of the future.

dynaCERT will be exhibiting at Booth D15 in Hall 24 with demonstrations of its flagship products, the internationally renowned HG1 and HG2.

Daily presentations of the company's HydraLytica TM app will held at 11:00 am and 3:00 pm throughout the exhibition.

Enrico Schlaepfer, Vice President Global Sales & Marketing for dynaCERT , states, "As part of our CCF (Corporate Carbon Footprint) at dynaCERT , we not only want to reduce world-wide CO 2 e emissions with our HydraGEN™ Technology, but also feel compelled this year to make our booth at the "IAA Transportation" absolutely 100% climate neutral. We pursue an approach that is more transparent and comprehensible than a simple CO 2 e-Offset Certificate. For each component of our exhibit, we calculate the exact amount of CO 2 e emissions and then offset this GHG footprint by planting trees at the Hanover exhibition center and the surrounding area. The Company's HydraGEN™ Technology is the one technology that bridges the gap to the ecological transition and provides a cost-effective solution to the world today!"

Jim Payne, President & CEO of dynaCERT , comments, "After the unexpected planetary disruptions of the past two years caused by the COVID pandemic, dynaCERT is extremely pleased and very eager to be able to relaunch its high-profile global marketing drives and trade show initiatives. With our 47 dealers world-wide supported by our dedicated European and North American in-house professionals, we are strongly committed to furthering our international presence in 2022 and beyond."

For further information on IAA Transportation 2022, please visit their website at: https://www.iaa-transportation.com/en

dyna CERT Inc. manufactures and distributes Carbon Emission Reduction Technology for use with internal combustion engines. As part of the growing global hydrogen economy, our patented technology creates hydrogen and oxygen on-demand through a unique electrolysis system and supplies these gases through the air intake to enhance combustion, resulting in lower carbon emissions and greater fuel efficiency. Our technology is designed for use with many types and sizes of diesel engines used in on-road vehicles, refrigerated trailers, off-road construction, power generation, mining and forestry equipment, marine vessels and railroad locomotives. Website: www.dynaCERT.com .

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance of achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; the uncertainty of the emerging hydrogen economy; including the hydrogen economy moving at a pace not anticipated; our ability to secure and maintain strategic relationships and distribution agreements; and the other risk factors disclosed under our profile on SEDAR at www.sedar.com . Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Neither The Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of The Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of the release.

On Behalf of the Board Murray James Payne, CEO

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005057/en/

Jim Payne, CEO & President dynaCERT Inc. #101 – 501 Alliance Avenue Toronto, Ontario M6N 2J1 +1 (416) 766-9691 x 2 jpayne@ dynaCERT .com

Investor Relations dynaCERT Inc. Nancy Massicotte +1 (416) 766-9691 x 1 nmassicotte@ dynaCERT .com

News Provided by Business Wire via QuoteMedia

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that it has signed an agreement with Caris Life Sciences ® (Caris), a leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare.

"Our goal is to develop immunotherapies that are personalized for each patient, and Caris' extensive library of clinical data, cutting-edge biomarker technology, and expertise will be invaluable in achieving our objectives," stated Dr. Giuseppe Del Priore, BriaCell's Chief Medical Officer. "We expect Caris' unique platform to help us identify patients who do not respond to existing treatments and are more likely to benefit from our immunotherapy treatments."

Under the terms of the agreement, Caris will help BriaCell with efficient patient identification, accelerating enrollment for its current Phase I/II clinical trial in advanced metastatic breast cancer of certain genetically defined subgroups. The partnership between BriaCell and Caris leverages Caris' Right-In-Time (RIT) Clinical Trial Network, a group of over 495 oncology sites that are able to quickly identify and enroll eligible patients in biomarker-directed clinical trials. This service offers patients and physicians access to the most cutting-edge precision medicine in development. Additionally, through Caris' comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing), Caris will perform tumor profiling for the patients enrolled in the clinical trial.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .

Caris Life Sciences ® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.

With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris' latest advancement is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow Caris on Twitter ( @CarisLS ).

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact: William V. Williams, MD President & CEO 1-888-485-6340 info@briacell.com

Media Relations: Jules Abraham Director of Public Relations CORE IR 917-885-7378 julesa@coreir.com

Investor Relations Contact: CORE IR investors@briacell.com

Caris Life Sciences Media Contact: Lisa Burgner corpcomm@carisls.com 214-294-5606

News Provided by GlobeNewswire via QuoteMedia

GOAT Industries Ltd. (the " Company " or " GOAT ") (CSE: GOAT), is pleased to announce the Company has entered into a non-binding Letter of Intent (the " LOI ") dated September 14, 2022 with 1000288601 Ontario Inc. (" Ontario Co ").

The LOI contemplates a proposed transaction (the " Proposed Transaction "), whereby GOAT would acquire all issued and outstanding securities of Ontario Co by way of a share exchange agreement (the " Share Exchange "). Ontario Co is in the process of acquiring the Canadian license for a Direct Lithium Extraction technology (the " DLE Technology ") developed by private industry, as well as University researchers based out of Australia.

It is the Company's understanding that the DLE Technology is more cost-effective extraction technology than fractional crystallization, membrane filtering, MOF's, adsorption, reverse osmosis, and ion exchange.

The DLE Technology has the potential to reduce capital and operating costs, while accelerating battery metal project startups via:

The proposed transaction is expected to be completed pursuant to available prospectus exemptions in accordance with applicable securities legislation. GOAT and Ontario Co have agreed to negotiate in good faith the terms of a definitive written agreement with respect to the proposed transaction within 60 days from the LOI. The proposed transaction is subject to receipt of all necessary regulatory approvals, including, as applicable, approval of the Canadian Securities Exchange (CSE), completion of due diligence reasonable or customary in a transaction of a similar nature and entering into a definitive agreement, among other conditions. The proposed transaction would be an arm's-length transaction for GOAT and would not constitute a fundamental change or result in a change of control of the company, within the meaning of the policies of the CSE.

GOAT Industries is an investment issuer focused on investing in high-potential companies operating across a variety of sectors. The paramount goal of the Company will be to generate maximum returns from its investments.

The Company's final prospectus, financial statements and management's discussion and analysis, among other documents, are all available on its profile page on SEDAR at www.sedar.com .

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING "FORWARD-LOOKING" INFORMATION

This news release contains certain forward-looking statements within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. The Company has provided the forward-looking statements in reliance on assumptions that it believes are reasonable at this time. All such forward-looking statements involve substantial known and unknown risks and uncertainties (including those risk factors identified in the Company's prospectus dated February 15, 2022), certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, delays resulting from or inability to obtain required regulatory approval. The reader is cautioned that the assumptions used in the preparation of the forward-looking statements may prove to be incorrect and the actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits, including the amount of proceeds, the Company will derive therefrom. Readers are cautioned that the foregoing list of factors is not exhaustive. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

GOAT Industries Ltd. Investor Relations Email: alex@goatindustries.co Phone: 604-687-2038

News Provided by GlobeNewswire via QuoteMedia

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

KWESST Micro Systems Inc. (TSXV: KWE) ("KWESST" or "the Company") announced today that it has commenced an underwritten public offering in Canada of units for gross proceeds of approximately USD$3 million (the "Offering"). Each unit (a "Unit") is comprised of one common share in the capital of KWESST (a "Share") and a common share purchase warrant (a "Warrant"). Each Warrant entitles its holder to purchase one additional common share for a period of five years from closing. PI Financial Corp. is acting as book-runner and sole underwriter in connection with the Offering.

The Offering is expected to close concurrently with the financing announced by KWESST on August 16th, 2022 for which ThinkEquity, a US based investment bank, will serve as sole book-running manager (the "US Financing"). Contingent on the closing of the US Financing, KWESST has applied to list its common shares on the Nasdaq Capital Market under the ticker symbol "KWE" and the warrants offered in the US Financing under the ticker symbol "KWESW".

The Offering is expected to be priced in the context of the market, with the final terms of the Offering to be determined at the time of pricing. The price of the Offering will be identical to the price of the US Financing and the Warrants will be exercisable at the same price as those issued as part of the US Financing and will have the same expiry date. The shares are expected to be listed on the TSX Venture Exchange (the "TSXV"). The Offering will be subject to the terms of an underwriting agreement to be entered into between the Company and PI Financial Corp. Closing of the Offering is subject to customary conditions as well as the successful completion of the US Financing and the listing on Nasdaq Capital Market having been approved.

The Company intends to use the net proceeds from the Offering to repay certain outstanding loans and for general corporate purposes.

The Company filed a preliminary short form base PREP prospectus (the "Preliminary Prospectus") in connection with the Offering. The Preliminary Prospectus was filed with the securities commissions in each of the provinces of Canada, except Québec.

The Preliminary Prospectus contains important detailed information about the Offering. The Preliminary Prospectus can be found under the Company's profile on SEDAR at www.sedar.com. Copies of the Preliminary Prospectus may also be obtained from PI Financial Corp. by email at: syndication@pifinancial.com. Prospective investors should read the Preliminary Prospectus and the other documents the Company has filed before making an investment decision.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the "United States" or to "U.S. persons" (each as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and all applicable state securities laws or an exemption from such registration requirements is available.

For more information, please visit https://kwesst.com/

Contact: Steve Archambault, CFO, archambault@kwesst.com or (613) 317-3941 Jason Frame, Investor Relations: frame@kwesst.com

KWESST develops and commercializes breakthrough next-generation tactical systems that meet the requirements of security forces and personal defense for overmatch capability against adversaries. The company's current portfolio of unique proprietary offerings include its unique non-lethal PARA OPSTM system with application across all segments of the non-lethal market, including law enforcement and personal defence. KWESST is also engaged in the digitization of tactical forces for shared situational awareness and targeting with its signature TASCS Situational Control System) for real-time awareness and targeting information from any source (including drones) streamed directly to users' smart devices and weapons. Other KWESST products include counter-measures against threats such as drones, lasers and electronic detection. These include the autonomous GreyGhostTM soldier-portable micro drone missile system that defends against small hostile drones including swarms using high-speed kinetic impact; a Ground Laser Defence system to counter the emerging threat of weaponized lasers against personnel and the PhantomTM electronic battlefield decoy system to mask the electromagnetic signature of friendly forces with decoy signatures at false locations to deceive and confuse adversaries. These systems can operate stand-alone or integrate seamlessly with OEM products and battlefield management systems. The Company is headquartered in Ottawa, Canada, with operations in Stafford, VA and representative offices in London, UK and Abu Dhabi, UAE. KWESST trades on the TSX Venture Exchange under the symbol KWE.

This press release contains "forward-looking information" within the meaning of Canadian Securities laws, which may include, but are not limited to: KWESST's plans to consummate the Offering and US Financing, the size of the Offering and US Financing, the completion of the Offering and US Financing; the pricing and final terms of the Offering and US Financing; listing of the Unit Shares on the TSXV and the listing of KWESST's shares on NASDAQ; entering into an underwriting agreement with respect to the Offering; use of the net proceeds from the Offering; and KWESST's business, production and products. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such information and statements are based on the current expectations of KWESST's management and are based on assumptions and subject to risks and uncertainties. Although KWESST's management believes that the assumptions underlying such information and statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting KWESST, including risks relating to: the failure to complete the Offering; the failure to obtain TSXV approval; general economic and stock market conditions; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States and elsewhere; the ability of KWESST to implement its business strategies; risks and uncertainties detailed from time to time in KWESST's filings with the Canadian Securities Administrators; and many other factors beyond the control of KWESST.

Although KWESST has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information or statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information or statement can be guaranteed. Except as required by applicable securities laws, forward-looking information and statements speak only as of the date on which they are made and KWESST undertakes no obligation to publicly update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/136905

News Provided by Newsfile via QuoteMedia

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.

Large Stock,S0 Low Mini Order Quantity

Excellent Performance, Accurate Dimension, Fast Delivery

Top-Ranking Supplier

Bloom Health Partners CEO to Speak at Health Benefits Nation Conference in Orlando

Featured Products

News & Blog

How a safari camp in the heart of Kenya’s Masai Mara is harvesting 200kg monthly

EARL ON CARS - Palm Beach Florida Weekly

ico-cad

ico-cad

Water crisis: New ‘floating’ station could be key to unlimited clean drinking water | Science | News | Express.co.uk

Search

Water Filter Cartridges Market Size 2022 And Analysis By Top KeyPlayers – Koch Membrane Systems, Innovative Membrane Technologies (IMT bv), Pentair X-Flow, Critical Process Filtration – San Juan Independent

Water Filter Cartridges Market Size 2022 And Analysis By Top KeyPlayers – Koch Membrane Systems, Innovative Membrane Technologies (IMT bv), Pentair X-Flow, Critical Process Filtration – San Juan Independent

Insights on the Water Purifier Global Market to 2027 -

Laboratory Water Purifier Market 2022 Booming Across the Globe by BIOBASE Group, Aqua Solutions Inc., Evoqua Water Technologies Corp., Biosan, Thermo Fisher Scientific Inc., Merck KGaA – Indian Defence News